Our search strategy included keywords related to glioma subtypes, molecular markers (such as IDH mutations and 1p/19q co-deletions), and systemic therapies including therapeutics like temozolomide, PCV, and bevacizumab. This evidence concerns the gene IDH2 and glioma.